Email updates

Keep up to date with the latest news and content from BMC Clinical Pathology and BioMed Central.

Open Access Case report

Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature

Maryam Maghbool1, Mani Ramzi2, Inga Nagel3, Pablo Bejarano4, Reiner Siebert3, Abolfazl Saeedzadeh1 and Yahya Daneshbod1*

Author affiliations

1 Department of Molecular Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran

2 Department of Hematology- Oncology, Shiraz University of Medical Sciences, Shiraz, Iran

3 Institute of Human Genetics, Christian-Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

4 Department of Pathology, JMH/University of Miami School of Medicine, Miami, USA

For all author emails, please log on.

Citation and License

BMC Clinical Pathology 2013, 13:17  doi:10.1186/1472-6890-13-17

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1472-6890/13/17


Received:2 January 2013
Accepted:22 May 2013
Published:31 May 2013

© 2013 Maghbool et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Primary adenocarcinoma of thymus is extremely rare.

Case presentation

This is a case of primary adenocarcinoma with intestinal differentiation and focal mucin production in the thymus. Thymic cyst was associated with this tumor. Intestinal differentiation was confirmed by immunohistochemical stain with positivity for CDX-2, CK20, villin, MOC31 and focal positivity of CK7. Array comperative genomic hybridization (CGH) analysis showed a complex pattern of chromosomal imbalances including homozygous deletion at the HLA locus in chromosomal region 6p21.32.

Conclusion

This rare tumor shows a similar genetic aberration with other studied thymic epithelial tumors.

Keywords:
Thymus gland; Primary adenocarcinoma; Intestinal differentiation; Thymic carcinoma; Thymoma; Molecular study; CGH array; Immunohistochemical study; Literature review

Background

Primary thymic carcinomas are very rare tumors. The most common histologic subtypes are squamous cell, adenosquamous/mucoepidermoid, basal cell, large cell undifferentiated, adenocarcinoma, carcinoma with adenoid cystic carcinoma-like features, lymphoepithelioma-like, clear cell, and sarcomatoid carcinomas [1]. Primary thymic adenocarcinoma was first reported in 1989 [2] but has not been accepted as a valid histologic subtype until 1997 [3]. These are uncommon neoplasms. Papillary adenocarcinoma and mucinous adenocarcinoma are the most common variants [1,4-6]. Therefore, before a diagnosis of a de novo thymic adenocarcinoma, other possible diagnoses such as: metastatic carcinoma, thymoma and adenocarcinoma arising in a mediastinalteratoma should be excluded [1,7]. There is little genetic data for thymic carcinomas other than squamous cell carcinomas [8], so we applied a genetic study by array comperative genomic hybridization (CGH) analysis on this case.

Case presentation

A 28 year old woman presented with neck and right upper extremity pain accompanied by dyspnea of two years duration. Chest X- ray revealed mediastinal widening (Figure 1A). Chest computed tomography (CT) scan (Figure 1B) showed an anterior mediastinal mass invading in pericardium without extramediastinal extension. An initial clinical impression of a mediastinal germ cell tumor was considered but serum tumor markers such as alpha-feto protein (AFP), Beta-human chorionic gonadotropin (β-hCG), carcinoembryonic antigen (CEA) and CA-125 were normal. CA19-9 level was 2420 U/ml (normal: 0.37U/ml). A mediastinal biopsy was done and showed histologic features of adenocarcinoma. Endoscopy, colonoscopy, abdominopelvicsonography and imaging studies were negative for primary origin. The patient underwent mid-sternotomy. The mass was resected. The patient received chemotherapy (GEMOX) and radiotherapy with two recurrences in 2 years follow up. She is doing well and free of tumor after 6 months.

thumbnailFigure 1. Representative images of radiology, histology, immunostaining as well as results of array-comparative genomic hybridization (array-CGH). A: Chest X ray showed mediastinal widening. B: chest CT scan revealed anterior mediastinal mass that invade pericardium. C: tumoral sheets and glandular structures in desmoplasticstroma (H&E stain, × 400). D: Malignant glands showed diffuse membranous positivity for CD5. (Immunoperoxidase). E: nuclear positivity for CDX-2 in malignant glands (Immunoperoxidase). F: Malignant glands showed diffuse positivity for CK20 (Immunoperoxidase). G: benign columnar linningthymic cyst adjacent to neoplastic glands (H&E stain, × 200). H: neoplastic glands arising in the vicinity of thymic cyst (H&E stain, × 200). I: Array-CGH-results displayed in a whole genome view showed deletion of chromosome 6. J: Homozygously deleted region around the HLA-DRB5-locus in chromosomal region 6p21.32.

Pathologic findings

The mediastinal biopsy showed a moderately differentiated adenocarcinoma with a desmoplastic and necrotic stroma (Figure 1C). Scattered small mucinous lakes were noted in the stroma. The stroma also showed foci of calcification and occasional psammoma bodies. Intracytoplasmic and stromal positive reactions were seen on mucicarmin stain. The excised tumor showed similar morphological and immunohistochemical characteristics. In one of the sections, a unilocunar large cyst with columnar epithelium, in vicinity of the tumor was also identified (Figure 1G, H). Small foci of remnant of thymic tissue were identified. Immunohistochemical (IHC) study showed positivity for CK, EMA, CK20 (Figure 1D), CDX-2 (Figure 1E), CK7, CD5 (Figure 1F), villin, HMWK(focal) and MOC31 but ER, PR, TTF-1, GCDFP-15, P63, CD30, PLAP, chromogranin, calretinin and CD117 were all negative. Commercial sources, clones, and working dilutions of antibodies used in the study are listed in Table 1. Extensive histologic and immunohistochemical study of the whole specimen showed no evidence of teratomatous or germ cell elements.

Table 1. Comercial sources, clones, and working dilutions of antibodies used in this case

Genetic abberations in formalin-fixed paraffin-embedded tissue

Array CGH on this case was performed using the Human Genome Microarray 180A platform (Agilent, Santa Clara, USA). The experimental procedures were performed according to the protocols provided by the manufacturers. Slides were scanned with the G2565CA Microarray Scanner (Agilent) at a scan resolution of 5 μm. Signal intensities from the generated images were measured and evaluated with Feature Extraction 10.10.11 and Agilent Genomic Standard Workbench Edition 6.5.0.58 (AGW6.5) software (Agilent) applying the Aberration Detection Method-2 (ADM-2) algorithm with a threshold of 6.0. It showed a complex karyotype with multiple gains and losses. Part of the HLA-DR5 locus in chromosomal region 6p21.32 seemed to be homozygously deleted (Figure 1I, J).

Consent

“Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.”

Discussion

Metastatic neoplasms to the mediastinum account for most of epithelial cell neoplasms. The second most common tumors are thymoma and thymic carcinoma. Primary adenocarcinoma is very rare in mediastinum, so before considering this diagnostic entity, most prevalent tumors such as metastatic adenocarcinomas, germ cell tumors and malignant teratomas must be ruled out [1,3-5,7,8]. Through clinical history, imaging studies, absence of extramediastinal tumor and histology, we report a case of primary adenocarcinoma with intestinal differentiation of the thymus with mucin production.

Immunostains are an important tool in the study of mediastinal tumors. For instance CD5 is a leukocyte marker expressed on differentiating thymocytes. It is said to be useful in differentiating thymic from non-thymic carcinomas [4,7,8]. Caution must be given because CD5 is positive in malignant pleural mesothelioma and adenocarcinomas of other (non thymic origin) organs [4,8]. It is also important to exclude tumors derived from the lung and pleura by evaluating TTF-1 and calretinin.

The exact origin of thymic adenocarcinoma is not clear. Glandular differentiation is rarely seen in ultrastructural studies of normal thymic epithelial cells [5]. Also, in the involuted thymus, glandular or tubular structures can be found [7]. Therefore, adenocarcinomas can result from extreme glandular differentiation during tumor progression.

Review of the literature on thymic adenocarcinoma is shown in Tables 2 and 3. Twenty-six cases have been reported. Patients range in age from 15 to 82 years (mean 50 y ±17 y). Male/female ratio is 1.9/1. The most common morphologic subtypes are papillary carcinoma (38%), mucinous adenocarcinoma (34%), conventional adenocarcinoma (0.11%), NOS (0.07%) and papilotubular carcinoma (0.07%). Median age is 52.56 years. Associated findings are thymic cyst in 26% (mostly seen in mucinous subtype), thymoma in 11% (only in papillary subtype) and psammoma bodies in 15% (mostly seen in papillary subtype). Serum tumor markers were increased. CEA in 23% (mostly seen in mucinous subtype), B-HCG in 0.38% (only in conventional subtype) and CA19-9 in 11% (one papillary, one NOS and two mucinous subtypes, including ours). Immunohistochemistry on different subtypes were performed in a limited number of papers and showed positivity in CK7 (7/11), CK20 (6/9), CEA (6/9), Leu M1 (4/5), B-HCG (1/2), CDX-2 (3/4), Muc2 (1/2), Muc5 (2/2), CD5 (8/12), P63 (1/2), CA-19-9 (3/3), CAM5.2 (2/2), CK5,6 (1/2), P53 (2/2), Her2 (1/2) [4-7,9-18].

Table 2. Literature review of clinicopathological data of primary thymic adenocarcinomas

Table 3. Clinicopathologic data of the thymic adenocarcinoma reported in literature according to the four major subtypes

In our case the adenocarcinoma was associated with a large benign thymic cyst with columnar epithelium. It showed no dysplastic change.

Most of the patients with thymic adenocarcinoma do not have any chief complaint (41%). In symptomatic group, the most common presenting sign is chest pain (0.17%). Other rare signs are cough (0.05%), dyspnea (0.05%), and shoulder pain (0.05%). Weight loss is a rare sign in this tumor (0.05%). Anterior mediastinum is the most common location (79%) followed by right, left, substernal and pretracheal mediastinum (each below%1). Prognosis cannot be accurately evaluated due to low incidence rate of thymic adenocarcinoma. Some patients underwent surgical resection (15 cases), chemotherapy (12 cases) or radiotherapy (19 cases). Clinical outcome showed local recurrences (2 cases), metastatic disease (3 cases) and death due to surgical complication or disease (9 cases). According to Table 3, mucinous has much worse prognosis than papillary carcinoma (p value < 0.05). There are diverse genetic heterogenecity in thymic tumors. Genetic characterization has concentrated on WHO types A, B3, and C that harbors few lymphocytes [22]. No chromosomal gain is seen in type A and AB thymomas [8]. Simultaneous gain of 1q and loss of chromosome 6, and 13q aberrations frequently detected in type B3 thymomas. Loss of heterozygosity (LOH) on chromosome 6 is the most frequent genetic abnormality in thymoma. Recent studies on genetic alterations of thymoma based on (LOH) analyses inferred two different genetic pathways of tumorigenesis of thymoma, and heterogeneous genetic alterations in subtypes of thymoma, were identified by CGH and LOH analyses [22,23]. One of the important findings in the thymic epithelial tumor is frequent and multiple genetic aberrations of chromosome 6 that are found in 77.5 percent of them. There are five hotspots of frequent deletions indicating that several putative tumor suppressor genes on chromosome 6 are involved in the development of thymic epithelial tumor [8,22,23]. Deletion sites such as 6q21, 6q23, and 6q25-27 are well established in thymoma. As Zhou et al. reported; the most frequent LOH was found in the 6q23.3-25.3 chromosomal region and the second hot spot of deletions was located in the 6p21 region containing the major histocompatibility (MHC) classes I and II gene loci [22,24].

In our case, the HLA-DRB5-locus in chromosomal region 6p21.32 was homozygously deleted, showing similar genetic aberrations with other thymic epithelial tumors.

Conclusion

This primary adenocarcinoma of the thymus with intestinal differentiation shows homozygous deletion of part of the HLA- locus in chromosomal region 6p21.32 confirmed by CGH array. It is associated with a benign thymic cyst. This is the first genetic study on a primary thymic adenocarcinoma (mucinous type), which shows a similar genetic aberration with other thymic epithelial tumors. We suggest adding genetic study to clinicopathologic and imaging workup for confirmation of diagnosis of a primary thymic tumor.

Competing interests

No conflict of interest is declared, and source of funding is Dr. Daneshbod Laboratory.

Authors’ contributions

YD, MM, MR and AS were involved in diagnosis, conception, design, acquisition of data, analysis and interpretation of data and were directly involved in drafting and revising the manuscript. IN and RS were participated in the array CGH, analysis and interpretation of data and revising the manuscript. PB reviewed this case and confirmed the diagnosis as well as extensively revised the paper. All authors read and approved the final manuscript.

Acknowledgements

We like to thank Professor K. Daneshbod for his scientific comments and guidance and Mrs. F. Hadad, for performing immunohistochemicalstainings.

References

  1. Takahashi F, Tsuta K, Matsuno Y, Takahashi K, Toba M, Sato K, Uekusa T, Izumi H, Nakamura K, Hirose S, Fukuchi Y: Adenocarcinoma of the thymus:mucinous subtype.

    Hum Pathol 2005, 36:219-223. PubMed Abstract | Publisher Full Text OpenURL

  2. Moriyama S, Shimizu N, Kurita A, Teramoto S, Taguchi K: A case of adenocarcinoma of the thymus.

    Nihon KyobuGekaGakkaiZasshi 1989, 37:717-722. OpenURL

  3. Shimosato Y, Mukai K: Tumors of the mediastinum. Atlas of tumor pathology, third series, fascicle 21. Washington, DC: Armed Forces Institute of Pathology; 1997:120-158. OpenURL

  4. Kapur P, Rakheja D, Bastasch M, Molberg KH, Sarode VR: Primary mucinous adenocarcinoma of the thymus: a case report and review of the literature.

    Arch Pathol Lab Med 2006, 130:201-204. PubMed Abstract | Publisher Full Text OpenURL

  5. Matsuno Y, Morozumi N, Hirohashi S, Shimosato Y, Rosai J: Papillary carcinoma of the thymus: report of four cases of a new microscopic type of thymic carcinoma.

    Am J SurgPathol 1998, 22:873-880. OpenURL

  6. Makino Y, Asada M, Suzuki T, Hashimoto M: A case of adenocarcinoma of the thymus.

    Jpn J Thorac Cardiovasc Surg 1998, 46:1168-1171. PubMed Abstract | Publisher Full Text OpenURL

  7. Choi WW, Lui YH, Lau WH, Crowley P, Khan A, Chan JK: Adenocarcinoma of the thymus: report of two cases, including a previously undescribed mucinous subtype.

    Am J Surg Pathol 2003, 27:124-130. PubMed Abstract | Publisher Full Text OpenURL

  8. Shimosato Y, Mukai K: Tumors of the mediastinum. Atlas of tumor pathology, forth series, fascicle 11. American Registry of Pathology: Washington, DC; 2010. OpenURL

  9. Sawai T, Inoue Y, Doi S, Ikuta Y, Kimino K, Nakashima M, Soda H, Kohno S: Tubular adenocarcinoma of the thymus: case report and review of the Literature.

    Int J Surg Pathol 2006, 14:243-246. PubMed Abstract | Publisher Full Text OpenURL

  10. Misao T, Yamamoto Y, Nakano H, Toyooka S, Yamane M, Satoh K: Primary thymic adenocarcinoma with production of carbohydrate antigen 19–9 and carcinoembryonic antigen.

    JpnJ ThoracCardiovascSurg 2004, 52:30-32. OpenURL

  11. Seki E, Aoyama K, Ueda M, Haga T, Nakazato Y, Iijima M, Kojima M, Tanaka R: Mucinous adenocarcinoma of the thymus: a case report.

    J Thorac Oncol 2008, 3:935-937. PubMed Abstract | Publisher Full Text OpenURL

  12. Yoshino M, Hiroshima K, Motohashi S, Shibuya K, Iyoda A, Sekine Y, Fujisawa T: Papillary carcinoma of the thymus gland.

    Ann Thorac Surg 2005, 80:741-742. PubMed Abstract | Publisher Full Text OpenURL

  13. Ra SH, Fishbein MC, Baruch-Oren T, Shintaku P, Apple SK, Cameron RB, Lai CK: Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature.

    Am J Surg Pathol 2007, 31:1330-1336. PubMed Abstract | Publisher Full Text OpenURL

  14. Furtado A, Nogueira R, Ferreira D, Tente D, Eisele R, Parente B: Papillary adenocarcinoma of the thymus: case report and review of the literature.

    Int J Surg Pathol 2010, 18:530-533. PubMed Abstract | Publisher Full Text OpenURL

  15. Hosaka Y, Tsuchida M, Umezu H, Eimoto T, Hashimoto T, Shinohara H, Hayashi J: Primary thymic adenocarcinoma coexisting with type AB thymoma: a rare case with long-term survival.

    Gen Thorac Cardiovasc Surg 2010, 58:488-491. PubMed Abstract | Publisher Full Text OpenURL

  16. Toshiji I, Mitsuaki S, Tsutomu S, Takashi M, Toshio K, Kazuhisa T: Thymic adenocarcinoma with sarcomatoid features characterized byIntracaval tumor growth: report of a case.

    Surg Today 2010, 40:1068-1072. PubMed Abstract | Publisher Full Text OpenURL

  17. Maeda D, Ota S, Ikeda S, Kawano R, Hata E, Nakajima J: Mucinous adenocarcinoma of the thymus: a distinct variant of thymic carcinoma.

    Lung Cancer 2009, 64:22-27. PubMed Abstract | Publisher Full Text OpenURL

  18. Ra YJ, Bae MJ, Kim YS, Choi KU: Difficulties in diagnosis and treatment of thymic adenocarcinoma producing β-human chorionic gonadotropin in anterior mediastinum.

    Interact Cardiovasc Thorac Surg 2010, 11:114-116. PubMed Abstract | Publisher Full Text OpenURL

  19. Babu MK, Nirmala V: Thymic carcinoma with glandular differentiation arising in a congenital thymiccyst.

    J Surg Oncol 1994, 57:277-279. PubMed Abstract | Publisher Full Text OpenURL

  20. Shimono M, Hiraki A, Ueoka H, Tanimoto Y, Aoe M, Sakae K, Kaneda K, Sakugawa M, Kiura K, Harada M: Successful treatment with concurrent chemoradiotherapy followed by surgery for a patient with thymic adenocarcinoma.

    Anticancer Res 2001, 21:2519-2522. PubMed Abstract OpenURL

  21. Zaitlin N, Rozenman J, Yellin A: Papillary adenocarcinoma in athymic cyst: a pitfall of thoracoscopic excision.

    Ann Thorac Surg 2003, 76:1279-1281. PubMed Abstract | Publisher Full Text OpenURL

  22. Lee GY, Yang WI, Jeung HC, Kim SC, Seo MY, Park CH, Chung HC, Rha SY: Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization.

    BMC Genomics 2007, 8:305. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  23. Inoue M, Starostik P, Zettl A, Ströbel P, Schwarz S, Scaravilli F, Henry K, Willcox N, MüllerHermelink H-K, Marx A: Correlating genetic aberrations with world health organization defined histology and stage across the spectrum of thymomas.

    Cancer Res 2003, 63:3708-3715. PubMed Abstract | Publisher Full Text OpenURL

  24. Zhou R, Zettl A, Ströbel P, Wagner K, Müller-Hermelink HK, Zhang SSJ, Marx A, Starostik P: Thymic epithelial tumors can develop along two different pathogenetic pathways.

    Am J Pathol 2001, 159:1853-1860. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6890/13/17/prepub